A consistent increase in AR expression was found in additional primary and established melanoma cells selected for BRAFi resistance by immunoblot and immunofluorescence analysis (IF) as well as RT-qPCR (Fig. 1b, c, Supplementary Fig. 1a-c, Supplementary Fig. 1f-m), with variable changes in MAPK expression and activation, consistent with previous publications20 (Supplementary Fig. 1n). The gene discussed is AR; the disease is melanoma.